Miho Maeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miho Maeda has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Yoshitaka Fukunaga
Department of Pediatrics
9 shared publicationsTakahiro Ueda
Department of Pediatrics
5 shared publicationsTakeshi Asano
Department of Pediatrics, Nippon Medical School
5 shared publicationsJun Hayakawa
Department of Pediatrics, Nippon Medical School
4 shared publicationsMakoto Migita
Department of Pediatrics, Nippon Medical School
4 shared publicationsAkio Tsuda
Department of Pediatrics, Nippon Medical School, Tokyo, Japan
2 shared publications
Latest Publications
- 1 October 2015
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 21 (10) , 751-755
Two cases with bacteremia suspected to be due to relatively rare Pseudomonas (Flavimonas) oryzihabitans
- 1 October 2015
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 21 (10) , 751-755
Two cases with bacteremia suspected to be due to relatively rare Pseudomonas (Flavimonas) oryzihabitans
- 16 April 2013
- Published by Wiley in Pediatrics International
- Vol. 55 (2) , 248-251
Successful coil embolization for life-threatening hemorrhage in childhood leukemia induction therapy
An 11‐year‐old boy was experienced severe life‐threatening hemorrhage from a branch of the superior mesenteric artery (SMA) after acute lymphoblastic leukemia induction therapy. The patient had a history of attention deficit hyperactivity disorder (ADHD), diagnosed at 3 years of age. Subsequent to discontinuing his psychotropic medication, the patient’s mental status deteriorated and treatment with midazolam for 3 weeks was necessary to allow the completion of the leukemia induction regimen. On day 51, although there was no indication of thrombocytopenia or a coagulation disorder, the patient began to hemorrhage suddenly from anal with resulting hypovolemic shock, and large‐volume blood transfusion was initiated. Although upper and lower endoscopy failed to determine the location of the hemorrhage, angiography enabled us to determine that it was a branch of the SMA (the middle colic artery #6), and selective arterial embolization was used to arrest the bleeding. There could have been underlying causes, such as, a probable malformation or aneurysm in that area, although there was no indication before or after the event. This is a rare case of arterial hemorrhage from a branch of the SMA that occurred in a pediatric patient idiopathically during the induction therapy of leukemia.
- 16 April 2013
- Published by Wiley in Pediatrics International
- Vol. 55 (2) , 248-251
Successful coil embolization for life-threatening hemorrhage in childhood leukemia induction therapy
An 11‐year‐old boy was experienced severe life‐threatening hemorrhage from a branch of the superior mesenteric artery (SMA) after acute lymphoblastic leukemia induction therapy. The patient had a history of attention deficit hyperactivity disorder (ADHD), diagnosed at 3 years of age. Subsequent to discontinuing his psychotropic medication, the patient’s mental status deteriorated and treatment with midazolam for 3 weeks was necessary to allow the completion of the leukemia induction regimen. On day 51, although there was no indication of thrombocytopenia or a coagulation disorder, the patient began to hemorrhage suddenly from anal with resulting hypovolemic shock, and large‐volume blood transfusion was initiated. Although upper and lower endoscopy failed to determine the location of the hemorrhage, angiography enabled us to determine that it was a branch of the SMA (the middle colic artery #6), and selective arterial embolization was used to arrest the bleeding. There could have been underlying causes, such as, a probable malformation or aneurysm in that area, although there was no indication before or after the event. This is a rare case of arterial hemorrhage from a branch of the SMA that occurred in a pediatric patient idiopathically during the induction therapy of leukemia.
- Open Access
- 10 April 2011
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 9 (1) , 22
Validation of the Japanese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module
Background: The PedsQL 3.0 Cancer Module is a widely used instrument to measure pediatric cancer specific health-related quality of life (HRQOL) for children aged 2 to 18 years. We developed the Japanese version of the PedsQL Cancer Module and investigated its reliability and validity among Japanese children and their parents. Methods: Participants were 212 children with cancer and 253 of their parents. Reliability was determined by internal consistency using Cronbach's coefficient alpha and test-retest reliability using intra-class correlation coefficient (ICC). Validity was assessed through factor validity, convergent and discriminant validity, concurrent validity, and clinical validity. Factor validity was examined by exploratory factor analysis. Convergent and discriminant validity were examined by multitrait scaling analysis. Concurrent validity was assessed using Spearman's correlation coefficients between the Cancer Module and Generic Core Scales, and the comparison of the scores of child self-reports with those of other self-rating depression scales for children. Clinical validity was assessed by comparing the on- and off- treatment scores using Kruskal-Wallis and Mann-Whitney U tests. Results: Cronbach's coefficient alpha was over 0.70 for the total scale and over 0.60 for each subscale by age except for the 'pain and hurt' subscale for children aged 5 to 7 years. For test-retest reliability, the ICC exceeded 0.70 for the total scale for each age. Exploratory factor analysis demonstrated sufficient factorial validity. Multitrait scaling analysis showed high success rates. Strong correlations were found between the reports by children and their parents, and the scores of the Cancer Module and the Generic Core Scales except for 'treatment anxiety' subscales for child reports. The Depression Self-Rating Scale for Children (DSRS-C) scores were significantly correlated with emotional domains and the total score of the cancer module. Children who had been off treatment over 12 months demonstrated significantly higher scores than those on treatment. Conclusions: The results demonstrate the reliability and validity of the Japanese version of the PedsQL Cancer Module among Japanese children.
- 10 April 2011
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 9 (1) , 22
Open AccessValidation of the Japanese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module
Background: The PedsQL 3.0 Cancer Module is a widely used instrument to measure pediatric cancer specific health-related quality of life (HRQOL) for children aged 2 to 18 years. We developed the Japanese version of the PedsQL Cancer Module and investigated its reliability and validity among Japanese children and their parents. Methods: Participants were 212 children with cancer and 253 of their parents. Reliability was determined by internal consistency using Cronbach's coefficient alpha and test-retest reliability using intra-class correlation coefficient (ICC). Validity was assessed through factor validity, convergent and discriminant validity, concurrent validity, and clinical validity. Factor validity was examined by exploratory factor analysis. Convergent and discriminant validity were examined by multitrait scaling analysis. Concurrent validity was assessed using Spearman's correlation coefficients between the Cancer Module and Generic Core Scales, and the comparison of the scores of child self-reports with those of other self-rating depression scales for children. Clinical validity was assessed by comparing the on- and off- treatment scores using Kruskal-Wallis and Mann-Whitney U tests. Results: Cronbach's coefficient alpha was over 0.70 for the total scale and over 0.60 for each subscale by age except for the 'pain and hurt' subscale for children aged 5 to 7 years. For test-retest reliability, the ICC exceeded 0.70 for the total scale for each age. Exploratory factor analysis demonstrated sufficient factorial validity. Multitrait scaling analysis showed high success rates. Strong correlations were found between the reports by children and their parents, and the scores of the Cancer Module and the Generic Core Scales except for 'treatment anxiety' subscales for child reports. The Depression Self-Rating Scale for Children (DSRS-C) scores were significantly correlated with emotional domains and the total score of the cancer module. Children who had been off treatment over 12 months demonstrated significantly higher scores than those on treatment. Conclusions: The results demonstrate the reliability and validity of the Japanese version of the PedsQL Cancer Module among Japanese children.
- 1 January 2011
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 78 (6) , 407-409
Gene Analysis of Nosocomial Infection due to Clostridium difficile
- 1 January 2011
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 78 (6) , 407-409
Gene Analysis of Nosocomial Infection due to Clostridium difficile
- Open Access
- 1 January 2008
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 75 (6) , 320-324
Late Effects of Childhood Cancer: Life-threatening Issues
Improvements in therapies for childhood cancers have increased the number of survivors. However, with this prolonged survival, the late effects of disease and anti-cancer therapy are becoming increasingly important. Approximately two-thirds of survivors of childhood cancer will have at least one late effect, and about one-third will have a late effect that is severe or life-threatening. A second neoplasm is one of the most severe late effects in survivors of childhood cancer. Compared with normal populations, persons with a history of childhood cancer have a 10- to 20-fold greater risk of a second malignant neoplasm. Patients who have undergone radiation therapy or been given specific chemotherapeutic agents and patients with a known genetic predisposition to malignancy have been shown to be at higher risk for a second malignant neoplasm. Cardiac problems are another serious late effect for survivors of childhood cancer. Anthracycline-induced cardiotoxicities are common in these patients. A cumulative dose of anthracycline greater than 300 mg/m2 is associated with an 11-fold higher risk of clinical heart failure compared with a cumulative dose of less than 300 mg/m2. Serial monitoring of cardiac functioning in children receiving anthracycline allows early identification of cardiac damage. One cardioprotectant (dexrazoxane) has proven effective in adult patients, but larger trials are needed to determine its efficacy in children. It is important to recognize that it may not be best to categorize surviving patients by primary diagnosis. Instead, strategies for surveillance of survivors should be based on the treatment each patient received.
- 1 January 2008
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 75 (6) , 320-324
Open AccessLate Effects of Childhood Cancer: Life-threatening Issues
Improvements in therapies for childhood cancers have increased the number of survivors. However, with this prolonged survival, the late effects of disease and anti-cancer therapy are becoming increasingly important. Approximately two-thirds of survivors of childhood cancer will have at least one late effect, and about one-third will have a late effect that is severe or life-threatening. A second neoplasm is one of the most severe late effects in survivors of childhood cancer. Compared with normal populations, persons with a history of childhood cancer have a 10- to 20-fold greater risk of a second malignant neoplasm. Patients who have undergone radiation therapy or been given specific chemotherapeutic agents and patients with a known genetic predisposition to malignancy have been shown to be at higher risk for a second malignant neoplasm. Cardiac problems are another serious late effect for survivors of childhood cancer. Anthracycline-induced cardiotoxicities are common in these patients. A cumulative dose of anthracycline greater than 300 mg/m2 is associated with an 11-fold higher risk of clinical heart failure compared with a cumulative dose of less than 300 mg/m2. Serial monitoring of cardiac functioning in children receiving anthracycline allows early identification of cardiac damage. One cardioprotectant (dexrazoxane) has proven effective in adult patients, but larger trials are needed to determine its efficacy in children. It is important to recognize that it may not be best to categorize surviving patients by primary diagnosis. Instead, strategies for surveillance of survivors should be based on the treatment each patient received.
- Open Access
- 19 November 2007
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (1) , 180-183
Ewing sarcoma/primitive neuroectodermal tumor of the kidney in a child
A 6‐year‐old female was admitted with abdominal pain and a mass in the right abdomen. Her lactose dehydrogenase level was 1,200 IU/L, and neuron specific enolase was 120 ng/ml. Computed tomography scan confirmed a large right renal mass with necrosis. A right radical nephrectomy was performed. The tumor was completely encapsulated. Based on small round cell histology, strong MIC‐2 (CD99) positive tumor cells, and EWS‐FLI‐1 fusion transcript, Ewing sarcoma/primitive neuroectodermal tumor of the kidney was diagnosed. Induction and follow‐up with seven cycles of chemotherapy were given after surgery. She has had no evidence of recurrence 90 months from diagnosis. Pediatr Blood Cancer 2008;50:180–183.
- 19 November 2007
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (1) , 180-183
Open AccessEwing sarcoma/primitive neuroectodermal tumor of the kidney in a child
A 6‐year‐old female was admitted with abdominal pain and a mass in the right abdomen. Her lactose dehydrogenase level was 1,200 IU/L, and neuron specific enolase was 120 ng/ml. Computed tomography scan confirmed a large right renal mass with necrosis. A right radical nephrectomy was performed. The tumor was completely encapsulated. Based on small round cell histology, strong MIC‐2 (CD99) positive tumor cells, and EWS‐FLI‐1 fusion transcript, Ewing sarcoma/primitive neuroectodermal tumor of the kidney was diagnosed. Induction and follow‐up with seven cycles of chemotherapy were given after surgery. She has had no evidence of recurrence 90 months from diagnosis. Pediatr Blood Cancer 2008;50:180–183.
- Open Access
- 1 January 2005
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 72 (5) , 252-253
Brain White Matter Changes during Treatment of a Child for Acute Lymphoblastic Leukemia
A 13-year old boy with acute lymphoblastic leukemia had bilateral paresis of the upper extremities and aphasia 1 week after high dose methotrexate and triple intrathecal therapy (methotrexate, cytarabin, hydrocortisone). The stroke-like neurological symptoms disappeared on the third day. T2-weighted magnetic resonance imaging showed hyperintensities of white matter on the second day. Despite resolution of the neurological symptoms, magnetic resonance images were still abnormal 3 years after the attack. Methotrexate has been considered to be responsible for ischemic damage to oligodendroglial cells, resulting in demyelination. The changes are occasionally prolonged without persistent neurologic symptoms.
- 1 January 2005
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 72 (5) , 252-253
Open AccessBrain White Matter Changes during Treatment of a Child for Acute Lymphoblastic Leukemia
A 13-year old boy with acute lymphoblastic leukemia had bilateral paresis of the upper extremities and aphasia 1 week after high dose methotrexate and triple intrathecal therapy (methotrexate, cytarabin, hydrocortisone). The stroke-like neurological symptoms disappeared on the third day. T2-weighted magnetic resonance imaging showed hyperintensities of white matter on the second day. Despite resolution of the neurological symptoms, magnetic resonance images were still abnormal 3 years after the attack. Methotrexate has been considered to be responsible for ischemic damage to oligodendroglial cells, resulting in demyelination. The changes are occasionally prolonged without persistent neurologic symptoms.
- Open Access
- 1 January 2005
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 72 (6) , 355-363
Clinical Aspects of Infant Leukemia-Experiences of a Single Institution of Japan: High Level of Serum Immunoglobulin M in Infant Leukemia
The prognosis and clinical and biological characteristics of infant leukemia differ from those of leukemia in children 1 year or older. We reviewed the charts of patients younger than 1 year in whom leukemia was diagnosed from January 1981 through December 2003 at our institution. Fourteen infants had leukemia, 6 had acute lymphoblastic leukemia (ALL), and 8 had acute myeloid leukemia (AML). The age of patients at diagnosis ranged from 2 to 11 months. Five of 8 AML patients presented with cutaneous manifestations, such as erythema and nodules, at diagnosis. Central nervous system (CNS) involvement was seen in 1 AML patient at diagnosis. Hyperleukocytosis of more than 50×109/L was seen in 4 of 6 ALL patients and in 4 of 8 AML patients at diagnosis. All ALL patients showed a morphological diagnosis of L1 using the French-America-British classification system. For patients with AML, the morphological diagnoses were M0 for 1 patient, M2 for 1 patient, M4 for 2 patients (1 with eosinophilia), M5b for 2 patients, and M7 for 2 patients. One patient showing M7 morphology had Down syndrome. Surface markers were examined in 5 of 6 ALL patients and all AML patients. Five ALL patients showed a B-cell precursor immunophenotype. Two of 5 patients with ALL had CD10-positive leukemic cells and 3 of 5 patients with ALL had CD10-negative leukemic cells. All AML patients were positive for CD13 or CD33 or both. Three of 5 patients with ALL showed abnormal chromosomes related to 11q. Six of 7 patients with AML showed abnormal karyotypes. MLL gene rearrangements were seen in 3 (2 ALL, 1 AML) of 5 (2 ALL, 3 AML) patients. Serum immunoglobulin M levels were increased in 9 of 14 patients. Complete remission (CR) was achieved in all infants with ALL. Three patients relapsed and then died of the original disease. One of these 3 patients died after cord blood transplantation. Three ALL patients are alive without leukemia. CR was achieved in 6 of 8 AML patients. Four of 6 patients are alive without leukemia. Infant leukemia patients in our institution had some special features. CNS involvement at diagnosis was seen in only 1 patient and serum IgM levels were higher than those in children whose leukemia was diagnosed at 1 to 10 years of age.
- 1 January 2005
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 72 (6) , 355-363
Open AccessClinical Aspects of Infant Leukemia-Experiences of a Single Institution of Japan: High Level of Serum Immunoglobulin M in Infant Leukemia
The prognosis and clinical and biological characteristics of infant leukemia differ from those of leukemia in children 1 year or older. We reviewed the charts of patients younger than 1 year in whom leukemia was diagnosed from January 1981 through December 2003 at our institution. Fourteen infants had leukemia, 6 had acute lymphoblastic leukemia (ALL), and 8 had acute myeloid leukemia (AML). The age of patients at diagnosis ranged from 2 to 11 months. Five of 8 AML patients presented with cutaneous manifestations, such as erythema and nodules, at diagnosis. Central nervous system (CNS) involvement was seen in 1 AML patient at diagnosis. Hyperleukocytosis of more than 50×109/L was seen in 4 of 6 ALL patients and in 4 of 8 AML patients at diagnosis. All ALL patients showed a morphological diagnosis of L1 using the French-America-British classification system. For patients with AML, the morphological diagnoses were M0 for 1 patient, M2 for 1 patient, M4 for 2 patients (1 with eosinophilia), M5b for 2 patients, and M7 for 2 patients. One patient showing M7 morphology had Down syndrome. Surface markers were examined in 5 of 6 ALL patients and all AML patients. Five ALL patients showed a B-cell precursor immunophenotype. Two of 5 patients with ALL had CD10-positive leukemic cells and 3 of 5 patients with ALL had CD10-negative leukemic cells. All AML patients were positive for CD13 or CD33 or both. Three of 5 patients with ALL showed abnormal chromosomes related to 11q. Six of 7 patients with AML showed abnormal karyotypes. MLL gene rearrangements were seen in 3 (2 ALL, 1 AML) of 5 (2 ALL, 3 AML) patients. Serum immunoglobulin M levels were increased in 9 of 14 patients. Complete remission (CR) was achieved in all infants with ALL. Three patients relapsed and then died of the original disease. One of these 3 patients died after cord blood transplantation. Three ALL patients are alive without leukemia. CR was achieved in 6 of 8 AML patients. Four of 6 patients are alive without leukemia. Infant leukemia patients in our institution had some special features. CNS involvement at diagnosis was seen in only 1 patient and serum IgM levels were higher than those in children whose leukemia was diagnosed at 1 to 10 years of age.
- Open Access
- 1 January 2004
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 71 (4) , 297-300
Two Children with Thalassemia Identified During Screening for Anemia in Junior High School
We present two Japanese students with thalassemia identified during screening for anemia in their junior high school. Blood test results revealed marked hypochromic and microcytic erythrocytosis in one patient and microcytic anemia in the other. Both cases showed a mean corpuscular volume/red blood cell (MCV/RBC) ratio less than 13. Their β/α synthesis ratio was elevated. Deletion of ψα2, ψα1, α2, α1 and &thetas;1 genes in the α-globin gene clusters were noted in the first case. This pattern of gene deletion was consistent with heterozygous α-thalassemia 1 of the Southeast Asian type. On the other hand, an increased hemoglobin A2 level and reduced β/α synthesis ratio were found in the second case. Direct cloning and DNA sequencing identified a point mutation (guanine to adenine) at position 1 of intervening sequence II in the β-globin gene (IVS II-1 G→A). These results suggest that this patient had heterozygous β0-thalassemia. Diagnosis of thalassemia should be confirmed by molecular analysis in cases with microcytic anemia or hypochromic microcytosis with a MCV/RBC ratio of 13 or less.
- 1 January 2004
- Published by Medical Association of Nippon Medical School in Journal of Nippon Medical School
- Vol. 71 (4) , 297-300
Open AccessTwo Children with Thalassemia Identified During Screening for Anemia in Junior High School
We present two Japanese students with thalassemia identified during screening for anemia in their junior high school. Blood test results revealed marked hypochromic and microcytic erythrocytosis in one patient and microcytic anemia in the other. Both cases showed a mean corpuscular volume/red blood cell (MCV/RBC) ratio less than 13. Their β/α synthesis ratio was elevated. Deletion of ψα2, ψα1, α2, α1 and &thetas;1 genes in the α-globin gene clusters were noted in the first case. This pattern of gene deletion was consistent with heterozygous α-thalassemia 1 of the Southeast Asian type. On the other hand, an increased hemoglobin A2 level and reduced β/α synthesis ratio were found in the second case. Direct cloning and DNA sequencing identified a point mutation (guanine to adenine) at position 1 of intervening sequence II in the β-globin gene (IVS II-1 G→A). These results suggest that this patient had heterozygous β0-thalassemia. Diagnosis of thalassemia should be confirmed by molecular analysis in cases with microcytic anemia or hypochromic microcytosis with a MCV/RBC ratio of 13 or less.
- 1 January 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (11) , 2291-2294
Marked Elevation of Soluble Fas Ligand and Cytokine Secretion after Splenectomy in Aggressive Natural Killer Cell Leukemia/Lymphoma
We report a case of Epstein - Barr virus-associated aggressive natural killer cell leukemia/lymphoma with giant splenomegaly in which splenectomy resulted in progression of apoptosis and hemophagocytosis. The serum level of ferritin, triglycerides, interferon-γ (IFN-γ), interleukin 10 (IL-10), and soluble Fas ligand (sFasL) increased markedly, and liver damage progressed after splenectomy. The number of apoptotic cells in peripheral blood smears increased following splenectomy. In the present case, splenectomy caused disruption of the cytokine network, resulting in apoptosis of blood cells and hepatocytes, as well as phagocytosis.
- 1 January 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (11) , 2291-2294
Marked Elevation of Soluble Fas Ligand and Cytokine Secretion after Splenectomy in Aggressive Natural Killer Cell Leukemia/Lymphoma
We report a case of Epstein - Barr virus-associated aggressive natural killer cell leukemia/lymphoma with giant splenomegaly in which splenectomy resulted in progression of apoptosis and hemophagocytosis. The serum level of ferritin, triglycerides, interferon-γ (IFN-γ), interleukin 10 (IL-10), and soluble Fas ligand (sFasL) increased markedly, and liver damage progressed after splenectomy. The number of apoptotic cells in peripheral blood smears increased following splenectomy. In the present case, splenectomy caused disruption of the cytokine network, resulting in apoptosis of blood cells and hepatocytes, as well as phagocytosis.